Accepted for/Published in: JMIR mHealth and uHealth
Date Submitted: Oct 25, 2018
Open Peer Review Period: Oct 25, 2018 - Dec 20, 2018
Date Accepted: Jun 19, 2019
(closed for review but you can still tweet)
Review of Mobile Health Technologies for Medication Compliance and Nutrition Tracking for Possible Use by the End Stage Renal Disease (ESRD) patients
ABSTRACT
Background:
Numerous free and low-cost mobile applications for tracking nutrition and medication compliance have become available in recent years. While these appear to be promising tools, they have not been evaluated comparatively based on common metrics, and thus limited evidence is available as to the efficacy of these applications. This study systematically cataloged and assessed mobile applications designed to assist medication compliance and nutrition tracking that are useful to the chronic kidney disease (CKD) and the End Stage Renal Disease (ESRD) patients who are on dialysis.
Objective:
The objective of this study is to comprehensively evaluate mobile apps used for medication compliance and nutrition tracking for possible use by the CKD/ESRD patients.
Methods:
A systematic review framework was applied to the search, screening, and assessment of apps in Google Play and iOS stores. We considered apps that have English as operating language, narrowed down further based on a set of inclusion and exclusion criteria, and then employed mobile apps rating scale (MARS), an app evaluation tool, to assess the effectiveness of apps that support CKD/ESRD patients.
Results:
Three apps have received the highest combined score by the review team. They are My Kidneys, My Health Handbook (= 4.63), My Food Coach (4.47), and H2O Overload (= 4.12).
Conclusions:
N/A
Citation
Per the author's request the PDF is not available.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.